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Summary
Background Patients with malignant melanoma often relapse after treatment with
BRAF and/or mitogen-activated protein kinase kinase (MEK) inhibitors (MEKi)
owing to development of drug resistance.
Objectives To establish the temporal pattern of CD271 regulation during develop-
ment of resistance by melanoma to trametinib, and determine the association
between development of resistance to trametinib and induction of prosurvival
autophagy.
Methods Immunohistochemistry for CD271 and p62 was performed on human
naevi and primary malignant melanoma tumours. Western blotting was used to
analyse expression of CD271, p62 and LC3 in melanoma subpopulations. Flow
cytometry and immunofluorescence microscopy was used to evaluate trametinib-
induced cell death and CD271 expression. MTS viability assays and zebrafish
xenografts were used to evaluate the effect of CD271 and autophagy modulation
on trametinib-resistant melanoma cell survival and invasion, respectively.
Results CD271 and autophagic signalling are increased in stage III primary mela-
nomas vs. benign naevi. In vitro studies demonstrate MEKi of BRAF-mutant mela-
noma induced cytotoxic autophagy, followed by the emergence of CD271-
expressing subpopulations. Trametinib-induced CD271 reduced autophagic
flux, leading to activation of prosurvival autophagy and development of MEKi
resistance. Treatment of CD271-expressing melanoma subpopulations with
RNA interference and small-molecule inhibitors to CD271 reduced the develop-
ment of MEKi resistance, while clinically applicable autophagy modulatory
agents – including D9-tetrahydrocannabinol and Vps34 – reduced survival of
MEKi-resistant melanoma cells. Combined MEK/autophagy inhibition also
reduced the invasive and metastatic potential of MEKi-resistant cells in an in vivo
zebrafish xenograft.
Conclusions These results highlight a novel mechanism of MEKi-induced drug resis-
tance and suggest that targeting autophagy may be a translatable approach to
resensitize drug-resistant melanoma cells to the cytotoxic effects of MEKi.
What’s already known about this topic?
• The targeted mitogen-activated protein kinase kinase (MEK) inhibitor (MEKi) tram-
etinib is used for the treatment of patients with BRAF-mutant metastatic melanoma
in combination with BRAF inhibitors, but many tumours rapidly develop resistance
to these drugs.
• Resistance of melanoma to trametinib has been associated with the induction of
prosurvival autophagy, but it is unclear how stem-cell markers, such as CD271
contribute to the transitionary phase of drug resistance.
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What does this study add?
• Transient induction of the low-affinity neurotrophin receptor CD271 is a critical
regulator of the adaptive drug–response phase of melanoma cells to trametinib.
• Genetic or chemical inhibition of CD271 prevents emergence of trametinib-
induced drug-resistant melanoma subpopulations.
• Progression to trametinib resistance by melanoma subpopulations results in loss of
CD271 expression and subsequent resistance to CD271 inhibitors, but not to the
cytotoxic effects of autophagy modulation.
What is the translational message?
• Autophagy modulation either through inhibition of vacuolar protein sorting 34, or
activation of cytotoxic autophagy with tetrahydrocannabinol effectively resensitizes
drug-resistant melanoma cells to trametinib in vitro and in vivo.
• Combined autophagy modulation and MEK inhibition offers a novel personalized
therapeutic strategy to overcome MEKi-induced drug resistance for patients with
BRAF-mutant metastatic melanoma.
Cutaneous melanoma remains the most deadly form of skin
cancer with a rapidly increasing global incidence.1 Oncogenic
BRAF mutations, such as the common V600E substitution pre-
sent in 30–50% of melanomas.2,3 activate the downstream
effector mitogen-activated protein kinase kinase (MEK) to drive
melanoma tumour growth. Despite improvements in clinical
outcome since the introduction of selective BRAF and MEK
inhibitors (BRAFi/MEKi) and immune checkpoint inhibitors,
development of resistance to these drugs remains a major
problem, with little improvement in overall patient survival.4–6
Proposed mechanisms of resistance to BRAFi/MEKi treatment
include selection of melanoma subpopulations with inherent
genetic/epigenetic changes,7,8 or the induction of generic
stress-induced response mechanisms that raise the survival
threshold of the cell.9–11 This manuscript describes how two
complementary mechanisms – CD271 signalling and autop-
hagy – interact to regulate resistance of metastatic melanoma
to the MEKi trametinib, as well as how they may be targeted to
overcome drug resistance as an improved therapeutic approach
for patients with melanoma.
CD271 (low-affinity nerve growth factor receptor, nerve
growth factor receptor or p75 neurotrophin receptor) is a
member of the tumour necrosis factor superfamily that is criti-
cal in determining cell survival or death decisions.12 Previous
studies indicate that CD271 expression within primary mela-
nomas correlates with a more aggressive tumour phenotype
and reduced patient survival,13 while isolated CD271-expres-
sing cells from primary melanomas initiate tumour growth in
immunocompromised NRG mice at a higher rate than CD271–
cells.14 Conversely, other studies suggest that, rather than
being a marker of distinctive melanoma-initiating subpopula-
tions, CD271 expression is induced during acquired resistance
to BRAF inhibition, DNA-damaging drugs or ethanol.15–19
Collectively, these studies indicate that CD271 is a biomarker
of tumour progression and is consistent with the concept that
CD271 signalling constitutes a stress-tolerance mechanism
within tumour cells.
Autophagy is the principal intracellular signalling mecha-
nism, responsible for the degradation and recycling of dam-
aged and/or excess proteins and organelles, and serves as a
critical regulator of the survival/death response of melanoma
cells.20,21 Previous studies have shown that BRAF inhibition
upregulates autophagy in patients with BRAF-mutant mela-
noma, whereas inhibition of autophagic flux with the lysoso-
mal inhibitor chloroquine (CQ) overcomes BRAF inhibitor-
induced resistance in several cancers, including brain, colorec-
tal and melanoma,22–24 suggesting that autophagy inhibition
may be beneficial for the control of drug-resistant tumours in
general. Conversely, as autophagy also has a tumour-suppressor
function, activation of autophagy, for example by cannabinoids
such as D9-tetrahydrocannabinol (THC) or cannabidiol, has
been shown to induce cytotoxicity of melanoma,25,26 which
may potentially overcome the resistance of melanoma to
BRAF/MEK inhibition.
In the present study we demonstrate that the induction of
CD271 and modulation of autophagy are part of a temporary
innate response by melanoma cells to drug-induced stress that
characterizes a stress-tolerant state preceding development of
drug resistance and tumour progression. Single-agent trame-
tinib was used as a time-efficient model for development of
drug resistance, which also occurs in response to BRAF inhibi-
tion or combined BRAFi + MEKi treatment at longer time
points.17 We show that inhibiting either CD271 or autophagy
using clinically relevant small-molecule inhibitors effectively
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targets the stress-tolerant state to induce death of MEKi-resis-
tant melanoma subpopulations. Moreover, using an in vivo zeb-
rafish xenograft of human melanoma we show reduced
metastatic potential of MEKi-resistant melanoma cells in
response to combined treatment with trametinib and a novel
Vps34 inhibitor PIK-III,27 while, importantly, having no
adverse effect on the development and survival of the zebra-
fish. This work underpins the clinical relevance of CD271 and
autophagy inhibition as a strategy to overcome the acquired
resistance of BRAF-mutant melanoma to mitogen-activated pro-
tein kinase pathway inhibitors.
Materials and methods
Use of patient-derived tissue
Written informed consent and full ethical permission for the
use of patient tissue, including naevi (benign, noninvasive),
primary cutaneous melanomas and normal melanocytes, was
obtained from the Newcastle and Tyneside 1 research ethics
committee in accordance with the Declaration of Helsinki
Principles (reference: NRES 08/H0906/95 + 5).
Immunohistochemistry
A retrospective cohort of formalin-fixed paraffin-embedded
(FFPE) benign naevi or American Joint Committee on Cancer
(AJCC) stage I, II or III primary melanomas at diagnosis (see
Appendix S1 for classification details; Supporting Informa-
tion)28 were obtained from the histopathology departments at
the Royal Victoria Infirmary (Newcastle upon Tyne) and the
University Hospital of North Durham (Durham). Semi-quanti-
tative immunohistochemical analysis of CD271 and p62 was
performed according to a preoptimized methodology, as
described in Appendix S1 (see Supporting Information).
In vitro culture of human cell lines
Cutaneous human metastatic melanoma cell lines WM35 (a gen-
erous gift from Professor Meenhard Herlyn, The Wistar Institute,
Philadelphia, PA, U.S.A.), A375 and SKmel28 (American Type
Culture Collection, Manassas, VA, U.S.A) were grown and main-
tained as described in Appendix S1 (see Supporting Informa-
tion). The authenticity of all cell lines was verified by melanA
staining and confirmation of NRAS/BRAF mutational status using
custom TaqMan SNP genotyping assays (Applera, Europe BV,
Cheshire, U.K.) for the presence of the most frequent mutations
observed in melanomas – NRASQ61L, NRASQ61A, BRAFV600E or
BRAfV600D – as previously described,29 and cultures were main-
tained for up to a maximum of 50 passages. For long-term trame-
tinib treatment of melanoma cell lines, each cell line was cultured
in complete culture media containing 16 nmol L1 trametinib,
which was changed every 3 days. When trametinib-resistant mel-
anoma subpopulations emerged they were passaged by
trypsinization as normal and maintained in complete culture
media containing fresh 16 nmol L1 trametinib.
Zebrafish xenograft assay
Transparent transgenic fli1-GFP Casper zebrafish were housed
under standard conditions on a constant 14 h on/10 h off
light cycle at 285°C. All animals were maintained according
to the ARRIVE guidelines under U.K. Home Office project
licence 604548 held by B.C, which adhere to the require-
ments of the Animals (Scientific Procedures) Act 1986 of the
U.K. Government and conformed to Directive 2010/63/EU of
the European Parliament. For full details of xenograft assay see
Appendix S1 (see Supporting Information).
Please see Appendix S1 (see Supporting Information) for
additional details.
Results
CD271 and autophagy in primary and metastatic
melanoma
The prognostic potential of CD271 and p62 as biomarkers of
disease progression was determined by their immunohisto-
chemical expression in a cohort of FFPE primary naevi and
melanomas of differing AJCC disease stage (Fig. 1a–c).28,30
CD271 expression was significantly greater in stage III primary
melanomas compared with naevi, stage I or stage II melanoma
(all P < 0001; Fig. 1b). Lowest CD271 expression was
observed in stage II melanomas, which was associated with
increased p62 expression (P = 0001; Fig. 1c).30 These data
suggest that AJCC stage-dependent CD271 expression corre-
lates with the level of p62 expression in melanomas (Fig. 1d).
Western blotting demonstrated variable CD271 expression in a
panel of metastatic melanoma cell lines, with greatest basal
expression in BRAFV600I-mutant WM35 melanoma cells
(Fig. S1; see Supporting Information), while expression in
BRAFV600E-mutant A375 and SKmel28 melanoma cells was
comparable to primary human melanocytes. Western blot
analysis also demonstrated CD271+ subpopulations isolated
from the WM35 cell line using CD271 antibody-tagged
microbeads and magnetic separation columns had reduced
p62 expression vs. CD271– cells (Fig. 1e), suggesting CD271-
expressing subpopulations have increased basal autophagy.
To determine the contribution of increased autophagy to
the survival of CD271-expressing subpopulations, CD271+
cells isolated from A375, WM35 and SKmel28 cell lines were
treated for 24 h with 10 lmol L1 CQ, which inhibits autop-
hagy by blocking lysosome/autophagosome fusion. Analysis
of 3-(4,5,dimethythiazol-2-y)-5-(3-carboxymethoxy-phenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) metabo-
lism demonstrated that CQ significantly inhibited the viability
of CD271+ cells (Fig. 1f), indicating CD271+ subpopulations
require autophagy for survival.
To determine the effect of increased CD271 expression on
p62, CD271 was exogenously overexpressed in WM35 cells.
Western blot analysis demonstrated reduced p62 expression in
WM35 cells overexpressing CD271 vs. WM35 wild-type cells
(Fig. 1g). The reduction in p62 is likely attributable to CD271
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signalling rather than generic stress resulting from the trans-
fection process as expression of several endoplasmic reticulum
stress-response genes [ATF4, XBP1, ATF6, TRB3 and DDIT3
(CHOP)] were not significantly altered (Fig. S1; see Supporting
Information).
CD271 expression and autophagic activity in response to
trametinib
Dose-escalation studies demonstrated that a clinically achiev-
able concentration of 16 nmol L1 trametinib induced 50–
60% cell death of BRAFV600-mutant melanoma cells after
3 days. Flow cytometry analysis of annexin V/propidium
iodide (PI)-stained A375 cells treated with 16 nmol L1 tram-
etinib for 28 days demonstrated induction of apoptosis up to
14 days post-treatment (Fig. 2a). Gating of live A375 cells co-
stained with annexinV/PI and anti-CD271 antibody revealed
the expression of CD271 on live melanoma subpopulations
following exposure to trametinib for 9 days (Fig. 2b). Trame-
tinib also induced the time-dependent expression of CD271 in
A375, WM35 and SKmel28 cells, with a concurrent reduction
in p62 and increase in LC3-II expression after 9 days of treat-
ment, indicating co-activation of autophagy and CD271 sig-
nalling (Fig. 2c, Fig. S2; see Supporting Information).
Treatment of WM266-4 BRAFV600D-mutant melanoma cells,
stably expressing the dual-tagged LC3–red fluorescent protein–
green fluorescent protein reporter construct,31–33 with trame-
tinib for 9 days also revealed an increase in red puncta and
the expression of CD271 in individual cells, also indicating
co-activation of autophagy and CD271 signalling (Fig. 2d,
Fig. S3; see Supporting Information). Treatment of A375 and
WM35 cells with trametinib for 9 days increased activity of
adenosine monophosphate-activated protein kinase (AMPK), a
known inducer of autophagy (Fig. 2e, Fig. S3; see Supporting
Information) and reduced adenosine triphosphate (ATP)
release (Fig. 2f, Fig. S2; see Supporting Information), both of
which indicate a switch to catabolic, prosurvival metabolism.
Furthermore, Western blot analysis demonstrated that treat-
ment of A375 cells with trametinib for 9 days increased phos-
phorylation of AMPK, which was reversed by treatment with
(a) (b) (c)
(d) (e)
(f) (g)
Fig 1. Expression and correlation of CD271 and the autophagy marker p62 in primary melanomas and metastatic melanoma cell lines. (a)
Representative photomicrographs of immunohistochemical CD271 staining (pink) in a human benign naevus and American Joint Committee on
Cancer (AJCC) stage I–III primary melanomas of increasing Breslow depth and spread (scale bars = 100 lm). Semi-quantitative scoring of (b)
CD271 and (c) p62 expression in naevi (n = 5) and AJCC stage I (n = 5), stage II (n = 15) and stage III (n = 7) primary melanomas. Each point
is the mean CD271 or p62 expression of 10 images taken of each naevus or primary melanoma  95% confidence interval [CI; one-way ANOVA
with Tukey’s post-hoc correction (*P = 0027, **P = 0001, ##P = 0007, ****P < 0001)]. (d) Schematic of observed pattern of CD271
expression (red line) during melanoma progression vs. previously reported biphasic expression of p62 (green line). (e) Representative Western
blot analysis of CD271 (75 KDa), p62 (65 KDa) and b-actin (42 KDa) expression in subpopulations of the WM35 metastatic melanoma cell line
isolated using CD271 antibody-tagged microbeads and magnetic separation columns. (f) Relative viability, as measured by 3-(4,5,dimethythiazol-
2-y)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) metabolism, of isolated CD271+ and CD271–
subpopulations from WM35, A375 and SKmel28 melanoma cell lines following 24-h treatment in the presence or absence of 10 lmol L1
chloroquine (CQ) [n = 18 replicates from three independent experiments; mean  95% CI, one-way ANOVA with Tukey’s post-hoc correction
(**P = 0003, ##P = 0001, ****P < 0001)]. ns, nonsignficant. (g) Representative Western blot analysis of CD271 (75 KDa), p62 (65 KDa) and
b-actin (42 KDa) expression in WM35 cells before and after lentiviral-mediated overexpression of CD271 (CD271 OE).
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dorsomorphin (Compound C, an ATP mimic that inhibits
AMPK)34 for the final 24 or 48 h (Fig. 2g). Collectively, these
results indicate that prolonged MEKi in BRAF-mutant
melanoma cells induces CD271 and AMPK phosphorylation,
while also increasing autophagy and disrupting cellular energy
production.
(a) (b)
(c) (d)
(e) (f) (g)
Fig 2. Trametinib induces CD271 expression and autophagic activity in melanoma cells in vitro. (a) Flow cytometry of AnnexinV–phycoerythrin
(PE)/propidium iodide (PI)-stained A375 melanoma cells for percentage live, dead, dying/apoptotic or dying/necrotic cell fractions in the
presence or absence of treatment with 16 nmol L1 trametinib (Tram) for 3, 6, 9, 14 or 28 days compared vs. dimethyl sulfoxide (DMSO)
treatment (percentages did not significantly change between time points following DMSO treatment, which is shown at day 3 only for clarity)
[n = 3 independent experiments; mean  95% confidence interval (CI), two-way ANOVA with Tukey’s post-hoc correction for comparison of dead
cells (##P = 0007, **P = 0001, ****P < 0001)]. (b) Representative flow cytometry plots of A375 cells stained with AnnexinV–PE/PI/anti-
CD271 following treatment for 9 days with 16 nmol L1 trametinib (mean  SD of three independent experiments). An oval gate over ‘live cells’
was used to quantify CD271 expression, shown in the right-hand panel. (c) Representative Western blot analysis for CD271 (75 KDa), phospho-
extracellular signal-regulated kinase [ERK (pERK); 42/44 KDa], total-ERK (42/44 KDa), p62 (65 KDa), LC3B (LC3-I upper band, 14 KDa; LC3-II
lower band, 16 KDa), cleaved poly (ADP-ribose) polymerase (Cle. PARP; 85 KDa) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 37
KDa) expression by A375 cells following treatment with DMSO or 16 nmol L1 trametinib for 3, 6 or 9 days. (d) Representative fluorescent
photomicrographs of LC3–red fluorescent protein (RFP)–green fluorescent protein (GFP) expressing WM266-4 melanoma cells stained with anti-
CD271 (purple) following treatment for 9 days with DMSO or 16 nmol L1 trametinib. LC3–RFP–GFP appears in cells as diffuse yellow/green
fluorescence in the absence of autophagy but marks autolysosomes with red fluorescent puncta during active autophagy (scale bars = 50 lm). (e,
f) Relative phospho-adenosine monophosphate-activated protein kinase (AMPK) activity or adenosine triphosphate (ATP) release by A375 cells
following treatment with 16 nmol L1 trametinib (Tram) or DMSO for 9 days, or 10 min in the presence of either 1 mmol L1 H2O2 or 10%
sodium dodecyl sulfate (SDS) as positive controls [n = 3 independent experiments; mean  95% CI, one-way ANOVA with Tukey’s post-hoc
correction (**P = 0002, ***P < 0001)]. (g) Representative Western blot analysis for phospho-AMPK (pAMPK; 62 KDa), total AMPK (tAMPK;
62 KDa) and GAPDH (37 KDa) expression by A375 cells following treatment with 16 nmol L1 trametinib for 9 days, alone or in the presence of
5 lmol L1 Compound C (CC) for the final 24 or 48 h.
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Effect of CD271 inhibition on cell viability and autophagic
activity
To determine whether trametinib-induced CD271 functions as
a prosurvival signalling mechanism contributing to drug toler-
ance, A375 and WM35 cells, pretreated for 9 days with
16 nmol L1 trametinib, were further treated for 72 h with
trametinib in combination with either the CD271 inhibitors
TAT-PEP5 (PEP5) or Ro08-2750 (Ro08), or, alternatively,
with small interfering RNA (siRNA) targeting CD271
(siCD271). Subsequent analysis of MTS metabolism demon-
strated that chemical inhibition or siCD271 reduced the viabil-
ity of trametinib-treated A375 and WM35 cells vs. trametinib
treatment alone or following transfection with a scrambled
siRNA, respectively (Fig. 3a, b). Western blot analysis demon-
strated that siCD271 of A375 or WM35 cells following treat-
ment with trametinib for 9 days reduced p62 and increased
LC3-II expression vs. a scrambled siRNA, indicating increased
autophagy in response to loss of CD271 (Fig. 3c, Fig. S4; see
Supporting Information). Conversely, CD271 inhibitors did
not appear to alter p62 or LC3-II expression of A375 cells fol-
lowing treatment with trametinib for 9 days (Fig. 3d), sug-
gesting PEP5 and Ro08 may reduce cell viability through
inhibition of multiple mechanisms. In contrast to previous
studies,17 overexpression of CD271 in A375 and WM35 cells
did not reduce trametinib-mediated inhibition of cell viability
(Fig. 1f, Fig. S4; see Supporting Information).
To determine the effect of basal CD271 expression on
response to trametinib, WM35 cells (with highest basal
CD271 expression) were transfected with siCD271 prior to
trametinib treatment. Western blot analysis confirmed knock-
down of CD271 expression following siCD271 in WM35 cells
for 24 or 72 h compared with cells transfected with a scram-
bled siRNA (Fig. 3e). Subsequent analysis of MTS metabolism
demonstrated siCD271 for 24 h prior to treatment with tram-
etinib for 24 or 72 h increased trametinib-mediated inhibition
of cell viability vs. cells transfected with a scrambled siRNA
(Fig. 3f). Collectively, these data suggest that in the context of
MEKi, CD271 contributes to development of drug resistance,
potentially mediated through reduced cytotoxic autophagy.
Harnessing autophagy modulation for the treatment of
mitogen-activated protein kinase kinase inhibitor-
resistant melanoma cells
Western blot analysis of A375 cells treated with 16 nmol L1
trametinib for 42 days demonstrated that MEKi-induced
CD271 expression peaked at approximately 9 days and
returned to baseline by 28 days (Fig. 4a). Peak CD271 expres-
sion was subsequently followed by increased p62 expression
and accumulation of total LC3 with a reduced LC3-II/LC3-I
ratio between 9 and 14 days (Fig. 4a, Fig. S5c; see Supporting
Information), indicating reduced autophagy as previously
described,35 which coincided with a return to full proliferative
and invasive potential, confirming development of drug resis-
tance. Previous studies suggest autophagy inhibition represents
a viable therapeutic approach to overcome resistance of
BRAFV600E-mutant brain tumour and melanoma cells to BRAF
inhibition.22,24 To determine the role of autophagy within
MEKi-resistant melanoma cells, A375 cells continuously treated
with 16 nmol L1 trametinib for 42 days were further treated
for 48 h with trametinib alone or in combination with
5 lmol L1 PIK-III, 10 lmol L1 CQ or 5 lmol L1 THC.
Subsequent analysis of MTS metabolism showed that inhibi-
tion of autophagy with PIK-III or CQ, or, alternatively, activa-
tion of autophagy with THC, in combination with trametinib,
reduced the viability of MEKi-resistant melanoma cells
(Fig. 4b). Western blot analysis of A375 cells treated with
5 lmol L1 PIK-III for 2, 6 or 24 h demonstrated a time-
dependent increase in p62 and reduction in the LC3-II/LC3-I
ratio, indicating inhibition of autophagy by PIK-III (Fig. 4c,
Fig. S5d; see Supporting Information). Furthermore, com-
bined treatment of MEKi-resistant A375 cells with trametinib
and CQ for 7 days reduced migration/invasion into collagen
compared with single-agent treatment (Fig. S5; see Supporting
Information).36 Collectively, these results indicate that autop-
hagy modulation can contribute to resistance of BRAF-mutant
melanoma cells to MEK inhibition.
In vivo efficacy of autophagy inhibition in a zebrafish
xenograft of human melanoma
To evaluate whether combined autophagy and MEK inhibition
reduces the invasive potential of MEKi-resistant melanoma
cells in vivo, we developed an embryonic zebrafish xenograft
model of human metastatic melanoma in which DiI-labelled
melanoma cells were injected into the yolk sac of 2-day post-
fertilization fli1-GFP casper zebrafish embryos (Fig. 5a).37–39
Zebrafish injected with trametinib-resistant A375 cells were
treated with dimethyl sulfoxide, 16 nmol L1 trametinib,
5 lmol L1 PIK-III or both drugs in combination for 3 days
by addition of drugs to E3 aquarium water (Fig. 5b–e). Anal-
ysis of cell movement from site of injection demonstrated that
combination treatment with trametinib and PIK-III signifi-
cantly reduced invasion of trametinib-resistant A375 cells
in vivo (Fig. 5f) compared with DMSO or single-agent treat-
ment. Moreover, the combination treatment regime induced
cell death, as evidenced by the release of DiI from melanoma
cells into the surrounding tissue. Importantly, the combination
treatment regime was well tolerated and all fish survived treat-
ment with no obvious developmental abnormalities after
3 days. Collectively, these results demonstrate that specific
autophagy inhibition overcomes the metastatic and survival
potential of MEKi-resistant melanoma cells in vitro and in vivo.
Discussion
This study aimed to determine mechanisms mediating the
resistance of BRAF-mutant melanoma cells to MEK-specific
inhibition and define innovative means through which to
overcome such resistance in a clinical setting. Our observa-
tions of reduced CD271 expression in AJCC stage II
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(a)
(c) (d)
(e) (f)
(b)
Fig 3. CD271 inhibition increases trametinib-induced loss of melanoma cell viability in vitro. (a, b) Relative viability of A375 and WM35
melanoma cells following treatment with 16 nmol L1 trametinib (Tram) for 9 days and then for a further 72 h in the presence or absence of
5 lmol L1 TAT-PEP5 (PEP5) or 10 mmol L1 Ro08-2750 (Ro08) CD271 inhibitors, or following transfection of scrambled nontarget (siScram)
or CD271 (siCD271) small interfering RNA (siRNA) [n = 18 replicates from three independent experiments; mean  95% confidence interval
(CI), one-way ANOVA with Tukey’s post-hoc correction for CD271 inhibitors (**P = 0001, ****P < 0001), or unpaired t-test for siRNA
(##P = 0009, ****P < 0001)]. (c) Representative Western blot analysis for CD271 (75 KDa), p62 (65 KDa), LC3B (14/16 KDa) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 37 KDa) expression by A375 or WM35 cells following pretreatment with 16 nmol L1
trametinib for 9 days, transfection with siScram or siCD271, and continued treatment with 16 nmol L1 trametinib (Tram) for a further 72 h.
(d) Representative Western blot analysis for CD271 (75 KDa), p62 (65 KDa), LC3B (14/16 KDa) and GAPDH (37 KDa) expression by A375 cells
following treatment with 16 nmol L1 trametinib (Tram) for 9 days and then for a further 72 h in the presence or absence of 5 mmol L1 PEP5
or 10 mmol L1 Ro08. (e) Representative Western blot analysis for CD271 (75 KDa) and b-actin (42 KDa) expression by WM35 cells following
transfection with siScram or siCD271 for 24 or 72 h. (f) Relative viability, as measured by 3-(4,5,dimethythiazol-2-y)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) metabolism, of WM35 cells following transfection with siScram or siCD271 for 24 or
72 h in the presence of 16 nmol L1 trametinib (Tram) relative to dimethyl sulfoxide-treated cells at either time point (n = 9 replicates from
three independent experiments; mean  95% CI, one-way ANOVA with Tukey’s post-hoc correction ****P < 0001).
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melanomas suggest that CD271 may have a tumour-suppressor
function in normal melanocytes that is lost in the early stages
of melanoma progression. However, increased CD271 expres-
sion in AJCC stage III tumours indicates that CD271 may
potentially give tumour cells a survival advantage during
metastasis.
We show that treatment of BRAF-mutant melanoma cell
lines with trametinib induced cytotoxic autophagy and subse-
quent cell death. However, prolonged exposure to trametinib
led to the emergence of drug-resistant melanoma subpopula-
tions characterized by a transient increase in CD271 expres-
sion, the inhibition of which resulted in increased trametinib-
induced cell death, indicating that CD271 functions as a
prosurvival mechanism in response to MEK inhibition. Trame-
tinib-induced CD271 signalling has recently been shown to
induce prosurvival DNA damage response pathways,18 and
data from the present study additionally suggest that such sig-
nalling may promote survival by inhibiting cytotoxic autop-
hagy as knock-down of trametinib-induced CD271 in WM35
melanoma cells resulted in increased autophagy and reduced
cell viability. However, results also suggest that CD271 may
have opposing effects on autophagy in unstressed cells, such
as CD271+ cells from treatment-na€ıve cell lines that appear to
require autophagy for survival vs. CD271+ cells undergoing
drug-induced stress, where CD271 appears to reduce cyto-
toxic autophagy. The role of CD271 as a component of
diverse and/or opposing signalling networks is supported by
recent studies characterizing CD271 as a regulator of the ‘phe-
notype switch’,40 and seems increasing likely given the large
number of CD271-interacting partners, as well as the ability
of CD271 to function as a homodimer,41 or to elicit sig-
nalling in the absence of ligand binding.42
Data from the present study suggest a model whereby
CD271 contributes to drug resistance by lowering autophagy
below the threshold for induction of apoptosis allowing the
cell to benefit from the prosurvival function of autophagy
(Fig. 6). Therefore, similarly to BRAFi-resistant brain tumour
and melanoma cells,22,24 it is likely that MEKi-resistant mela-
noma subpopulations maintain a low autophagic activity to
promote survival and metastasis, which can be subsequently
targeted with CQ or by the novel, selective autophagy inhibi-
tor PIK-III to reduce invasion and viability of MEKi-resistant
melanoma cells both in vitro and in vivo. These results also sup-
port our previous findings showing that mutant BRAF sup-
presses autophagy,43 and provide a clear rationale for
combining BRAFi/MEKi with clinically relevant inhibitors of
autophagy such as those targeting the autophagy regulatory
protein Vps34.
(a)
(c)
(b)
Fig 4. Inhibition of autophagy reduces the viability of trametinib-resistant melanoma cells. (a) Representative Western blot analysis for CD271 (75
KDa), p62 (65 KDa), LC3B (14/16 KDa) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 37 KDa) expression by A375 cells following
treatment with dimethyl sulfoxide (DMSO) or 16 nmol L1 trametinib (Tram) for 3, 9, 28 or 42 days. (b) Relative viability, as measured by 3-
(4,5,dimethythiazol-2-y)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) metabolism, of A375 cells following
treatment with 16 nmol L1 trametinib (Tram) for 42 days then for a further 48 h in the presence or absence of 16 nmol L1 trametinib alone
or in combination with 5 mmol L1 PIK-III, 10 mmol L1 chloroquine (CQ) or 5 mmol L1 D9-tetrahydrocannabinol (THC) [n = 18 replicates
from three independent experiments; mean  95% confidence interval, one-way ANOVA with Tukey’s post-hoc correction (**P = 0005,
****P < 0001)]. (c) Representative Western blot analysis for p62 (65 KDa), LC3B (14/16 KDa) and GAPDH (37 KDa) expression by A375 cells
following treatment with 5 mmol L1 PIK-III (Vps34 inhibitor) for 2, 6 or 24 h.
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(bi) (bii)
(ci) (cii)
(f)
(dii)
(eii)(ei)
(di)
(a)
Fig 5. Inhibition of Vps34 reduces invasion and increases death of trametinib-resistant melanoma cells in an in vivo zebrafish xenograft of
metastatic melanoma. (a) Schematic of zebrafish xenograft assay showing injection of approximately 250 DiI-labelled melanoma cells into the yolk
sac of 2-day postfertilization (dpf) zebrafish embryos prior to incubation at 33°C in atmospheric air for 72 h and subsequent analysis of
melanoma invasion. (b–e) Representative confocal images of zebrafish embryos following injection with DiI-labelled trametinib-resistant A375 cell
and treatment for 72 h with (bi, ii) dimethyl sulfoxide (DMSO), (ci, ii) 16 nmol L1 trametinib (Tram), (di, ii) 5 lmol L1 PIK-III or (ei, ii)
16 nmol L1 trametinib (Tram) + 5 lmol L1 PIK-III (16 Tram + 5 PIK-III) by addition of drugs to E3 media. (f) Invasive distance of trametinib
(Tram)-resistant A375 cells from injection site [n = 10 fish for each condition from five independent experiments; mean  95% confidence
interval, Kruskal–Wallis test with Tukey’s post-hoc correction (****P < 0001)]. GFP, green fluorescent protein; PBS, phosphate-buffered saline.
(a) (b) (c)
Fig 6. Hypothesized effect of mitogen-activated protein kinase kinase (MEK) and autophagy inhibition on growth, survival and invasion of
melanoma. (a) In normal growth conditions, activating BRAF mutations increase extracellular signal-regulated kinase (ERK) signalling to inhibit
adenosine monophosphate-activated protein kinase (AMPK) and maintain autophagic activity (Autoph.) within survival limits. (b) MEK inhibitors
(MEKi) de-represses AMPK and allows autophagy to increase above the upper survival threshold (*) leading to activation of apoptosis or growth
arrest. Subsequent activation of adaptive prosurvival signalling, such as CD271, contributes to drug resistance by lowering autophagic activity
below the threshold for apoptosis, allowing reactivation of cell growth, proliferation and invasion. (c) Treatment of drug-resistant melanoma with
specific autophagy inhibitors, such as PIK-III, reduces prosurvival autophagic activity below the lower survival threshold (#) leading to
accumulation of cytotoxic by-products and activation of apoptosis.
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However, as autophagy is also a tumour-suppressor mecha-
nism in normal cells clinical inhibition of autophagy may sen-
sitize patients to secondary tumour formation. Therefore, an
alternative approach may be to exacerbate autophagy, for
example with THC, which has been shown to activate cyto-
toxic autophagy through induction of endoplasmic reticulum
stress, specifically in cancer cells, with minimal adverse effect
on normal cell types.25,44
This study highlights the great potential of harnessing the
modulation of generic survival mechanisms, such as CD271
signalling and autophagy, as a means to overcome drug resis-
tance and more effectively treat patients with currently incur-
able metastatic melanoma. However, for these approaches to
be applied in the clinic, further in vivo validation, such as per-
formed by recent studies demonstrating the potential of
autophagy modulatory drugs in zebrafish,45 is required to
confirm their antitumourigenic efficacy with minimal off-tar-
get toxicity to normal cells. To this end, zebrafish are a useful
and versatile model organism for the study of cancer that
complement existing nonanimal models of melanoma, such as
skin equivalents,46 by providing a fast, cost-effective assay for
studying in vivo melanoma metastasis and drug response.
Further preclinical studies of specific autophagy inhibitors,
such as novel Vps34 inhibitors, or compounds and strategies
that specifically mediate induction of cytotoxic autophagy in
cancer cells, such as cannabinoids, will inform the design of
early-phase clinical trials and drive the efficacy of personalized
targeted medicine that harnesses autophagy modulation of the
benefit of patients with metastatic melanoma.
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Fig S1. (a) Representative Western blot analysis of CD271
and b-actin expression in primary human melanocytes
(M1058F, M1054F, M880F) and human metastatic melanoma
cell lines (WM35, A375 and SKmel28). (b) Densitometry
quantification of CD271 expression and (c) quantification of
CD271 mRNA transcript levels in primary human melanocytes
and human metastatic melanoma cell lines (n = 3 independent
Western blot replicates). (d–h) Relative expression of Xbp1,
ATF4, ATF6, TRB3 and CHOP mRNA transcript level in A375
melanoma cells flowing over expression of CD271 (CD271
OE).
Fig S2. (a) Densitometry quantification of CD271, p62 and
LC3-II expression by A375 cells following treatment with
dimethyl sulfoxide or 16 nmol L1 trametinib for 3, 6 or
9 days. (b, c) Representative Western blot analysis of CD271,
p62 and LC3, and densitometry quantification of CD271, LC3-
II and p62 expression (n = 3 independent Western blot repli-
cates), by WM35 and SKmel28 cells.
Fig S3. (a–c) Mean fluorescence intensity of LC3–red fluo-
rescent protein (RFP), LC3–green fluorescent protein (GFP)
and CD271–A647 staining by WM266-4 cells following treat-
ment with 16 nmol L1 trametinib for 9 days [n = 10
images; mean  95% confidence interval (CI), Mann–Whit-
ney test (*P = 0012, **P = 0002, ***P < 0001)]. (d) Rela-
tive phospho-adenosine monophosphate-activated protein
kinase (AMPK) activity or (e) adenosine triphosphate (ATP)
release by WM35 cells following treatment for 9 days in the
presence or absence of 16 nmol L1 trametinib, or 10 min in
the presence of either 1 mmol L1 H2O2 or 10% sodium
dodecyl sulfate (SDS) as positive controls [n = 3 independent
experiments; mean  95% CI, one-way ANOVA with Tukey’s
post-hoc correction, (*P = 0042, ****P < 0001)].
Fig S4. (a–d) Densitometry quantification of CD271, phos-
pho-adenosine monophosphate-activated protein kinase
(AMPK), p62 and LC3-II expression by A375 and WM35 cells
following treatment with 16 nmol L1 trametinib for 9 days
and then for a further 72 h following transfection with scram-
bled nontarget (siScram) or CD271 (siCD271) small interfer-
ing RNA (siRNA; n = 3 independent Western blot replicates).
(e) Densitometry quantification of CD271 and (f) quantifica-
tion of CD271 mRNA transcript levels in WM35 cells after 24,
96 and 168 h after transfection with siScram or siCD271. (g,
h) Relative viability, as measured by MTS metabolism, of
WM35 and A375 wild-type cells or cells overexpressing
CD271, following treatment in the presence or absence of
16 nmol L1 trametinib for 24, 48 or 72 h.
Fig S5. (a) Representative photomicrographs of A375
spheroids in type I collagen following treatment with 16 nmol
L1 trametinib for 42 days, and subsequently treated with
dimethyl sulfoxide (DMSO), 16 nmol L1 trametinib,
10 mmol L1 chloroquine or the combination of 16 nmol
L1 trametinib and 10 mmol L1 chloroquine [16 Tram + 10
chloroquine (CQ)] for 0, 2, 4 or 7 days; 910 magnification,
scale bar = 100 lm. (b) Invasion of A375 trametinib-resistant
spheroids relative to size at day 0 following the same treat-
ment protocol as for (a) [n = 24 cross-sectional diameters at
each time point from three independent experiments;
mean  SD, two-way ANOVA with Tukey’s post-hoc correction
(**P = 0002, ***P < 0001)]. (c) Densitometric quantifica-
tion of the ratio of LC3-II/LC3-I expression by A375 cells
treated for 3 days with DMSO, or for 3, 9, 14, 28 and
42 days with 16 nmol L1 trametinib (n = 3 independent
Western blot replicates). (d) Densitometric quantification of
the ratio of LC3-II/LC3-I expression by A375 cells treated for
0, 2, 6 or 24 h with 5 mmol L1 PIK-III (n = 3 independent
Western blot replicates).
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